These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34024874)

  • 1. To be Functional, or not to be Low in Cholesterol, that is the Clinical Concern when Evaluating Anti-Atherosclerotic Actions of High-Density Lipoproteins.
    Yoshida H
    J Atheroscler Thromb; 2021 Jul; 28(7):694-695. PubMed ID: 34024874
    [No Abstract]   [Full Text] [Related]  

  • 2. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
    Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
    Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High density lipoprotein, apolipoprotein A-I, and coronary artery disease.
    Srivastava RA; Srivastava N
    Mol Cell Biochem; 2000 Jun; 209(1-2):131-44. PubMed ID: 10942211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase.
    Shao B; Tang C; Sinha A; Mayer PS; Davenport GD; Brot N; Oda MN; Zhao XQ; Heinecke JW
    Circ Res; 2014 May; 114(11):1733-42. PubMed ID: 24647144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.
    Morton AM; Koch M; Mendivil CO; Furtado JD; Tjønneland A; Overvad K; Wang L; Jensen MK; Sacks FM
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins.
    Martinez LO; Najib S; Perret B; Cabou C; Lichtenstein L
    Atherosclerosis; 2015 Jan; 238(1):89-100. PubMed ID: 25437896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiinflammatory actions of HDL: a new insight.
    Rye KA; Barter PJ
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1890-1. PubMed ID: 18946054
    [No Abstract]   [Full Text] [Related]  

  • 8. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.
    Smith JD
    J Clin Lipidol; 2010; 4(5):382-8. PubMed ID: 21076633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin: cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells.
    Ohnsorg PM; Mary JL; Rohrer L; Pech M; Fingerle J; von Eckardstein A
    Biochim Biophys Acta; 2011 Dec; 1811(12):1115-23. PubMed ID: 21930241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health benefits of high-density lipoproteins in preventing cardiovascular diseases.
    Berrougui H; Momo CN; Khalil A
    J Clin Lipidol; 2012; 6(6):524-33. PubMed ID: 23312048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of dysfunctional high-density lipoprotein by myeloperoxidase.
    Nicholls SJ; Zheng L; Hazen SL
    Trends Cardiovasc Med; 2005 Aug; 15(6):212-9. PubMed ID: 16182131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in apolipoprotein A- I and it's anti-atherosclerosis properties].
    Li M; Liu ZM
    Sheng Wu Gong Cheng Xue Bao; 2003 Jul; 19(4):387-91. PubMed ID: 15969051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional HDL as a diagnostic and therapeutic target.
    Smith JD
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):151-5. PubMed ID: 19679832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High-density lipoproteins: the "new" target of cardiovascular medicine].
    Sampietro T; Bigazzi F; Dal Pino B; Puntoni M; Bionda A
    Ital Heart J Suppl; 2005 Jun; 6(6):341-53. PubMed ID: 16013425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease.
    Rohrer L; Hersberger M; von Eckardstein A
    Curr Opin Lipidol; 2004 Jun; 15(3):269-78. PubMed ID: 15166782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular Mechanism and Evaluation Method for Anti-Inflammatory HDL].
    Tanaka N; Ishida T
    Rinsho Byori; 2016 Jan; 64(1):49-56. PubMed ID: 27192797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function of different proportions of apolipoprotein A-I cysteine mutants and apolipoprotein A-V on recombinant high-density lipoproteins
    Yan Y; Lu S; Jia S; Dong Q; Wang L; Wang Y
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31023964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects.
    Toth PP
    Dis Mon; 2001 Aug; 47(8):369-416. PubMed ID: 11571478
    [No Abstract]   [Full Text] [Related]  

  • 19. Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans.
    Vaisar T; Shao B; Green PS; Oda MN; Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Nov; 9(5):417-24. PubMed ID: 18001626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunctional HDL and atherosclerotic cardiovascular disease.
    Rosenson RS; Brewer HB; Ansell BJ; Barter P; Chapman MJ; Heinecke JW; Kontush A; Tall AR; Webb NR
    Nat Rev Cardiol; 2016 Jan; 13(1):48-60. PubMed ID: 26323267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.